Reyvow generic
Reyvow is an anti-migraine drug that contains lasmiditan succinate as its active ingredient. It is owned by Eli Lilly And Co. The drug was first approved for market use on 31 January, 2020. Currently, Reyvow has three drug patents, of which one has already expired.
When will Reyvow generic be available?
The generic release of Reyvow is anticipated following the expiration of the last patent on 05 December, 2037. Therefore, it's possible that Reyvow generics could enter the market post this date.
Reyvow uses
Reyvow is primarily used for the acute treatment of migraines. The key component of this medication, lasmiditan succinate, aids in alleviating headache pain and other symptoms of a migraine attack.
Reyvow patent expiration
Reyvow is associated with three drug patents. The recently expired patent, US8748459, was titled 'Pyridinoylpiperidines as 5-HT1F agonists' and expired on 27 March, 2023. The remaining patents, US7423050 and US11053214, are expected to expire on 17 February, 2028, and 05 December, 2037, respectively. Keep an eye out for Reyvow generic release post these dates. Below are the details of the patent: